These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32532030)

  • 21. Enhancing endosomal escape for nanoparticle mediated siRNA delivery.
    Ma D
    Nanoscale; 2014 Jun; 6(12):6415-25. PubMed ID: 24837409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in siRNA delivery strategies for the treatment of MDR cancer.
    Subhan MA; Attia SA; Torchilin VP
    Life Sci; 2021 Jun; 274():119337. PubMed ID: 33713664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Confocal microscopy for the analysis of siRNA delivery by polymeric nanoparticles.
    Portis AM; Carballo G; Baker GL; Chan C; Walton SP
    Microsc Res Tech; 2010 Sep; 73(9):878-85. PubMed ID: 20803695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy.
    Kim YD; Park TE; Singh B; Maharjan S; Cho KS; Park KP; Choi YJ; Arote RB; Cho CS
    Curr Pharm Des; 2015; 21(31):4637-56. PubMed ID: 26486148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanotechnology for in vivo targeted siRNA delivery.
    Dahlman JE; Kauffman KJ; Langer R; Anderson DG
    Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced endosomal escape by photothermal activation for improved small interfering RNA delivery and antitumor effect.
    Yang X; Fan B; Gao W; Li L; Li T; Sun J; Peng X; Li X; Wang Z; Wang B; Zhang R; Xie J
    Int J Nanomedicine; 2018; 13():4333-4344. PubMed ID: 30087564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-Based Liquid Crystalline Nanoparticles Facilitate Cytosolic Delivery of siRNA via Structural Transformation.
    He S; Fan W; Wu N; Zhu J; Miao Y; Miao X; Li F; Zhang X; Gan Y
    Nano Lett; 2018 Apr; 18(4):2411-2419. PubMed ID: 29561622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic siRNA: principles, challenges, and strategies.
    Gavrilov K; Saltzman WM
    Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Advances in Engineering Carriers for siRNA Delivery.
    Yang C; Lin ZI; Zhang X; Xu Z; Xu G; Wang YM; Tsai TH; Cheng PW; Law WC; Yong KT; Chen CK
    Macromol Biosci; 2024 Apr; 24(4):e2300362. PubMed ID: 38150293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
    Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
    Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small interfering RNA-based molecular therapy of cancers.
    Guo W; Chen W; Yu W; Huang W; Deng W
    Chin J Cancer; 2013 Sep; 32(9):488-93. PubMed ID: 23327796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery strategies and potential targets for siRNA in major cancer types.
    Lee SJ; Kim MJ; Kwon IC; Roberts TM
    Adv Drug Deliv Rev; 2016 Sep; 104():2-15. PubMed ID: 27259398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy.
    Xu X; Saw PE; Tao W; Li Y; Ji X; Yu M; Mahmoudi M; Rasmussen J; Ayyash D; Zhou Y; Farokhzad OC; Shi J
    Nano Lett; 2017 Jul; 17(7):4427-4435. PubMed ID: 28636389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
    Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
    Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
    Hong CA; Nam YS
    Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.
    Prabhakar N; Zhang J; Desai D; Casals E; Gulin-Sarfraz T; Näreoja T; Westermarck J; Rosenholm JM
    Int J Nanomedicine; 2016; 11():6591-6608. PubMed ID: 27994460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
    Song Y; Tang C; Yin C
    Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances.
    Bidar N; Darroudi M; Ebrahimzadeh A; Safdari M; de la Guardia M; Baradaran B; Goodarzi V; Oroojalian F; Mokhtarzadeh A
    Eur J Pharmacol; 2022 Jan; 915():174639. PubMed ID: 34919890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use.
    Parashar D; Rajendran V; Shukla R; Sistla R
    Eur J Pharm Sci; 2020 Jan; 142():105159. PubMed ID: 31747618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.